Abstract

ObjectiveTo assess the efficacy and safety of tocilizumab (TCZ) plus methotrexate/placebo (MTX/PBO) over 2 years and the course of disease activity in patients who discontinued TCZ due to sustained remission.MethodsACT-RAY...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
POS0530 MOLECULAR SIGNATURE IN SUSTAINED CLINICAL REMISSION INDUCED BY TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
K Matsumoto ... K Suzuki
-
K Matsumoto, et. al.K Matsumoto ... K Suzuki
23 May 2022
SAT0255 Clinical and Radiographic Outcomes at 2 Years and the Effect of TOCILIZUMAB Discontinuation following Sustained Remission in the Second and Third Year of the ACT-RAY Study
M Aassi ... H Amital
Annals of the Rheumatic Diseases | VOL. 73
M Aassi, et. al.M Aassi ... H Amital
01 Jun 2014
Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
Eduardo Mysler ... Alejandra López
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | VOL. 26
Eduardo Mysler, et. al.Eduardo Mysler ... Alejandra López
01 Apr 2020
FRI0075 A multi-biomarker disease activity (vectra™ da algorithm) score and components are associated with sustained clinical remission in rheumatoid arthrits: the remira study.
G H Kingsley ... N Defranoux
Annals of the Rheumatic Diseases | VOL. 72
G H Kingsley, et. al.G H Kingsley ... N Defranoux
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers